Get the Stockscreener App
0.52
3.70%
-0.02
Pre-market:
.54
0.02
+3.85%
Clearmind Medicine Inc stock is traded at $0.52, with a volume of 179.91K.
It is down -3.70% in the last 24 hours and down -63.64% over the past month.
Clearmind Medicine Inc is a clinical-stage pharmaceutical company engaged in Phase I/IIa clinical trials of novel psychedelic medicines. The Company focuses on developing treatments for mental health disorders, including alcohol use disorder (AUD), binge drinking, and eating disorders. Its activities are centered on the research and development of 5-methoxy-2-aminoindane (MEAI). It operates through a single research and development segment, which is conducted in Israel.
See More
Previous Close:
$0.54
Open:
$0.55
24h Volume:
179.91K
Relative Volume:
0.04
Market Cap:
$5.30M
Revenue:
-
Net Income/Loss:
$-6.64M
P/E Ratio:
-0.0288
EPS:
-18.0702
Net Cash Flow:
$-5.60M
1W Performance:
-6.99%
1M Performance:
-63.64%
6M Performance:
-96.24%
1Y Performance:
-98.67%
1-Day Range:
$0.52
$0.5581
1-Week Range:
$0.52
$0.5966
52-Week Range:
$0.52
$52.40
Clearmind Medicine Inc Stock (CMND) Company Profile
Compare CMND vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CMND
Clearmind Medicine Inc
|
0.52 | 5.50M | 0 | -6.64M | -5.60M | -18.07 |
VRTX
Vertex Pharmaceuticals Inc
|
453.06 | 113.78B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
719.88 | 75.84B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
802.70 | 50.55B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
291.48 | 38.99B | 4.29B | 577.22M | 641.34M | 4.2086 |
ONC
Beone Medicines Ltd Adr
|
316.55 | 32.69B | 5.76B | 514.49M | 1.10B | 4.4813 |
Clearmind Medicine Inc Stock (CMND) Latest News
Number of shareholders of Clearmind Medicine Inc. – NASDAQ:CMND - TradingView
TradingKey - TradingKey
Clearmind Medicine Treats 20 Participants in CMND-100 Alcohol Use Disorder Trial - geneonline.com
20 patients treated in Clearmind (Nasdaq: CMND) Phase I/IIa AUD study - Stock Titan
Clearmind doses two more patients in alcohol disorder trial - Investing.com
Clearmind doses two more patients in alcohol disorder trial By Investing.com - Investing.com Canada
Clearmind Medicine Inc. Advances Phase I/IIa Trial of CMND-100 for Alcohol Use Disorder, Dosing Milestone Reached - Quiver Quantitative
Clearmind Medicine Reaches Important Clinical Milestone: 20 Participants Now Treated in Ongoing ... - Caledonian Record
Novel non-hallucinogenic alcohol use disorder drug reaches 20 patients - Stock Titan
Clearmind Medicine announces "Inside MEAI" webinar featuring new insights from CMND-100 psychedelic clinical trial - marketscreener.com
Webinar to unpack new data on non-hallucinogenic alcohol addiction drug candidate - Stock Titan
Clearmind Medicine Announces “Inside MEAI” Webinar Featuring New Insights from CMND-100 Psychedelic Clinical Trial - marketscreener.com
Clearmind shares surge as CMND-100 achieves primary endpoint in clinical trial - MSN
[EFFECT] Clearmind Medicine Inc. SEC Filing - Stock Titan
CMND: Clearmind Medicine Inc.Interactive Chart - Zacks Investment Research
Clearmind Medicine Stock Quote, Share Price, News and Analysis - Longbridge
Clearmind files European patent for PTSD treatment compounds By Investing.com - Investing.com South Africa
Clearmind files European patent for PTSD treatment compounds - Investing.com UK
Clearmind Medicine Inc. Files European Patent Application for Innovative Psychedelic Compounds Targeting PTSD Treatment - Moomoo
Clearmind (Nasdaq: CMND) files European patent for PTSD psychedelics - Stock Titan
Clearmind Medicine Announces Filing Of European Patent Application For Novel Psychedelic Compounds For The Treatment Of Ptsd - TradingView
Clearmind seeks European patent for psychedelic PTSD compounds - Stock Titan
Clearmind Medicine Announces Filing of European Patent Application for Novel Psychedelic ... - Caledonian Record
Clearmind Medicine Announces Filing of European Patent Application for Novel Psychedelic Compounds for the Treatment of PTSD - marketscreener.com
Clearmind Medicine Inc Announces Filing Of European Patent Application For Novel Psychedelic Compounds For Treatment Of PTSD - marketscreener.com
CMND SEC FilingsClearmind Medici 10-K, 10-Q, 8-K Forms - Stock Titan
CMND Forecast, Price Target & Analyst Ratings | CLEARMIND MEDICINE INC (NASDAQ:CMND) - ChartMill
Clearmind Medicine (NASDAQ: CMND) registers 22.6M resale shares tied to $10M notes - Stock Titan
Clearmind Medicine amends securities agreement and announces board changes By Investing.com - Investing.com South Africa
Clearmind Medicine amends securities agreement and announces board changes - Investing.com
Leadership shifts at Clearmind Medicine (NASDAQ: CMND) as chair exits - Stock Titan
Clearmind Announces Changes To Senior Management As It Accelerates Development Of Its IP Portfolio - TMX Newsfile
Clearmind Medicine regains compliance with Nasdaq - MSN
Clearmind Medicine to enact 1-for-40 reverse share split; shares down - MSN
Weekly Roundup on the Cannabis Sector & Psychedelic Sector - marketexclusive.com
Clearmind Medicine Announces Evaluation of its Psychedelic-Based Treatment (MEAI) for Potential FDA Breakthrough Therapy Designation - The Manila Times
Clearmind Medicine Inc. Pursues Breakthrough Therapy Designation for Alcohol Use Disorder Treatment CMND-100 Following Positive Clinical Trial Results - Quiver Quantitative
Clearmind (NASDAQ: CMND) explores FDA breakthrough path for CMND-100 in AUD - Stock Titan
Alcohol disorder treatment from Clearmind eyes FDA breakthrough path - Stock Titan
Why is Clearmind Medicine stock sliding on Wednesday? - MSN
CMND stock set for biggest intraday gains in over three years — here’s why retail is eyeing further upside - MSN
Clearmind Medicine Inc. (CMND) Stock Price Today - MEXC Exchange
CMND Technical Analysis | Trend, Signals & Chart Patterns | CLEARMIND MEDICINE INC (NASDAQ:CMND) - ChartMill
Why Is Clearmind Medicine Stock Sliding On Wednesday? - Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market SessionAxe Compute (NASDAQ:AGPU), Alpha Compute - Benzinga
Clearmind Medicine Inc Stock (CMND) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.58%
3.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):